Volume 22 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(2): 198-201
ZHANG Qiao, ZHOU Xuezhi, CHENG Sai, MENG Tao, GAO Zhengjie, ZHANG Dezhong, ZHU Shaohui. Clinical study on the therapeutic effect and prognostic value of peripheral blood inflammatory indexes in the treatment of advanced gastric cancer with immune checkpoint inhibitors[J]. Chinese Journal of General Practice, 2024, 22(2): 198-201. doi: 10.16766/j.cnki.issn.1674-4152.003364
Citation: ZHANG Qiao, ZHOU Xuezhi, CHENG Sai, MENG Tao, GAO Zhengjie, ZHANG Dezhong, ZHU Shaohui. Clinical study on the therapeutic effect and prognostic value of peripheral blood inflammatory indexes in the treatment of advanced gastric cancer with immune checkpoint inhibitors[J]. Chinese Journal of General Practice, 2024, 22(2): 198-201. doi: 10.16766/j.cnki.issn.1674-4152.003364
shu

Clinical study on the therapeutic effect and prognostic value of peripheral blood inflammatory indexes in the treatment of advanced gastric cancer with immune checkpoint inhibitors

doi: 10.16766/j.cnki.issn.1674-4152.003364
  • 1.

    Department of Gastrointestinal, Bariatric Metabolism and Hernia Surgery, the First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan 453100, China

Funds:

 82302298

 LHGJ20210523

 LHGJ20220597

 19A320003

  • Received Date: 2023-08-12
    Available Online: 2024-03-27
    Abstract
  •   Objective  To explore the efficacy and prognostic value of prognostic nutrition index (PNI), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) in advanced gastric cancer (AGC) treated with immune checkpoint inhibitors (ICIs).  Methods  A retrospective analysis was conducted on the clinical data of 75 AGC patients who received ICIs treatment at the First Affiliated Hospital of Xinxiang Medical College from June 2019 to January 2022. The ROC curve was used to calculate the optimal cutoff values for PNI, NLR, and PLR. Kaplan-Meier curves was plotted, and cox regression analysis was used to predict the independent risk factors affecting overall survival (OS) in AGC.  Results  The best cutoff values for PNI, NLR0, PLR0, and PLR4 were 36.00, 3.45, 186.65, and 138.23, respectively. The objective response rate (ORR) of high PNI group and low PLR0 group were higher. The disease control rate (DCR) of high PNI group, low NLR0 group, low PLR0 group and low PLR4 group were higher, and the differences were statistically significant (P<0.05). Univariate analysis showed that PNI, NLR0, PLR0, PLR4, BMI and stage were correlated with OS. Multivariate analysis showed that PLR0 was an independent risk factor for OS (HR=3.539, 95% CI: 1.717-7.296, P<0.001) and PFS (HR=4.556, 95% CI: 1.955-10.617, P<0.001) except stage.  Conclusion  Detection of PNI, NLR0, PLR0, and PLR4 has clinical guiding value for the efficacy and prognosis of AGC after ICIs treatment.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [2]
    SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648. doi: 10.1016/S0140-6736(20)31288-5
    [3]
    WANG H, GUO W H, HU Y F, et al. Superiority of the 8th edition of the TNM staging system for predicting overall survival in gastric cancer: comparative analysis of the 7th and 8th editions in a monoinstitutional cohort[J]. Mol Clin Oncol, 2018, 9(4): 423-431.
    [4]
    JOSHI S S, BADGWELL B D. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. doi: 10.3322/caac.21657
    [5]
    JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. doi: 10.1016/S0140-6736(21)00797-2
    [6]
    KANG Y K, CHEN L T, RYU M H, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 234-247. doi: 10.1016/S1470-2045(21)00692-6
    [7]
    SHITARA K, VANCUTSEM E, BANG Y J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. doi: 10.1001/jamaoncol.2020.3370
    [8]
    LINHARES P, FERREIRA A, VAZ R. The importance of the neutrophil-to-lymphocyte ratio in the prognosis of glioma and its subtypes[J]. CNS Neurosci Ther, 2020, 26(3): 394-395. doi: 10.1111/cns.13270
    [9]
    TAKECHI H, FUJIKUNI N, TANABE K, et al. Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective cohort study[J]. BMC Gastroenterol, 2020, 20(1): 256. doi: 10.1186/s12876-020-01402-z
    [10]
    DU S T, FANG Z H, YE L, et al. Pretreatment neutrophil-to-lym-phocyte ratio predicts the benefit of gastric cancer patients with systemic therapy[J]. Aging(Albany NY), 2021, 13(13): 17638-17654.
    [11]
    WU X B, HAN R K, ZHONG Y P, et al. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma[J]. Cancer Cell Int, 2021, 21(1): 356. doi: 10.1186/s12935-021-02072-x
    [12]
    WANG F H, ZHANG X T, LI Y F, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun(Lond), 2021, 41(8): 747-795.
    [13]
    马静, 胡博, 羊樟福, 等. 抗PD-1/PD-L1抗体单药及联合治疗晚期胆道癌相关不良反应管理进展[J]. 中国临床医学, 2022, 29(6): 1022-1029. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202206023.htm

    MA J, HU B, YANG Z F, et al. The adverse events management of anti-PD-1/PD-L1 antibody monotherapy and combination therapy in the treatment of advanced biliary tract cancer[J]. Chinese Journal of Clinical Medicine, 2022, 29(6): 1022-1029. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX202206023.htm
    [14]
    ZHOU Y X, ZHANG Y Q, GUO G F, et al. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer[J]. Clin Transl Med, 2020, 10(1): 107-115. doi: 10.1002/ctm2.14
    [15]
    BODOR J N, BOUMBER Y, BORGHAEI H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)[J]. Cancer, 2020, 126(2): 260-270. doi: 10.1002/cncr.32468
    [16]
    DENK D, GRETEN F R. Inflammation: the incubator of the tumor microenvironment[J]. Trends Cancer, 2022, 8(11): 901-914. doi: 10.1016/j.trecan.2022.07.002
    [17]
    SAHU A, KOSE K, KRAEHENBUEHL L, et al. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response[J]. Nat Commun, 2022, 13(1): 5312. doi: 10.1038/s41467-022-32738-7
    [18]
    SHI T, ZHANG Y P, WANG Y, et al. DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer[J]. Cancer Immunol Res, 2022, 10(12): 1506-1524. doi: 10.1158/2326-6066.CIR-22-0218
    [19]
    YAMAMOTO T, KAWADA K, OBAMA K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients[J]. Int J Mol Sci, 2021, 22(15): 8002. DOI: 10.3390/ijms22158002.
    [20]
    杨丽萍, 吴爱林, 周燕, 等. 放疗前NLR和PLR对局部晚期鼻咽癌患者预后的影响[J]. 中华全科医学, 2022, 20(9): 1458-1461, 1534. doi: 10.16766/j.cnki.issn.1674-4152.002622

    YANG L P, WU A L, ZHOU Y, et al. Effect of NLR and PLR from pre-radiotherapy on prognosis of locally advanced nasopharyngeal carcinoma patients[J]. Chinese Journal of General Practice, 2022, 20(9): 1458-1461. doi: 10.16766/j.cnki.issn.1674-4152.002622
    [21]
    JIANG Y, XU D, SONG H, et al. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis[J]. BMJ Open, 2021, 11(9): e048324. DOI: 10.1136/bmjopen-2020-048324.
    [22]
    把明勤, 陈柳, 朱小琼, 等. NRS2002和PNI营养筛查方法在胃癌患者预后中的预测价值[J]. 中华全科医学, 2023, 21(7): 1121-1124. doi: 10.16766/j.cnki.issn.1674-4152.003064

    BA M Q, CHEN L, ZHU X Q, et al. Predictive value of NRS2002 and PNI nutritional screening methods in the prognosis of patients with gastric cancer[J]. Chinese Journal of General Practice, 2023, 21(7): 1121-1124. doi: 10.16766/j.cnki.issn.1674-4152.003064
    [23]
    FENG J F, WANG L, YANG X, et al. Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: a real-world study[J]. Biomol Biomed, 2023, 23(1): 153-160.
    [24]
    LIU J J, LI S, ZHANG S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J]. J Clin Lab Anal, 2019, 33(8): e22964. DOI: 10.1002/jcla.22964.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (194) PDF downloads(28) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return